BRAF and neoplasm: PKM2 is significantly overexpressed in PTC, especially in cases harboring BRAF mutations, and its overexpression is closely related to advanced tumor stage and lymph node metastasis [60]; meanwhile, PKM2 knockdown significantly inhibits PTC cell growth, lactic acid and ATP production, and glucose consumption [61].